Phone
1300 884 450
info@melanomapatients.org.au
PO Box 1771
Toowong BC QLD 4066
Toowong BC QLD 4066
There is no one causal factor for developing melanoma. Factors that are associated with a higher risk of developing melanoma include:
“Melanoma patients will have a chance to prevent recurrence rather than just wait for disaster to strike”.
A/Prof Alexander Menzies and his colleagues discuss adjuvant targeted/immunotherapy for Stage 3 and how the future for melanoma patients is much less bleak these days thanks to these new drugs.
Melanoma blazes treatment trail for other cancers
afr.com
Other cancer patients will benefit if the government agrees to the early use of drugs to treat skin cancer.
I am on this trial, Stage III B-Raf positive, & hope the possibility of recurrence moves from 50% by 5yrs! So so grateful to Novartis!!
I feel privileged to be on this trial and had no success with one but having success with another, thanks for these trials.
Son was stage4 thank you six years latter he is stable.
Great article!
Trails are lifesaving
Amazing! This is an important read
Lesley Ann McMahon
Rose Cullen
At Melanoma Patients Australia our vision is:
‘Creating a world where no one affected by melanoma walks alone’.
We provide a range of patient-focused support and information services for all.
If you would like more information, please call our National Support Line on 1300 88 44 50 or
visit our website melanomapatients.org.au/
Researchers have discovered that melanoma cells with high numbers of faults in their DNA are more likely to respond immunotherapy drugs such as Keytruda and Opdivo.
Researchers Uncover Major Clue In Predicting Response To Immunotherapy
forbes.com
Immunotherapy continues to be one of the most talked-about therapeutic approaches in oncology, but one niggling issue has been puzzling researchers even since the early clinical trials: Why do patient...
Ellie wow! you said that this would be the way it would have to go!
Leeann Marriott
Here’s hoping mine is a total mutant.
Belinda Farley
Marie Govan
Interesting read
Pretty cool Ken Dutton-Regester!
Casey Sanders what u think
A Guide to Immunotherapy. Melanoma Patients Australia Ltd would like to share this short video to help explain this important form of treatment. Please share with family and friends.
So good that Melanoma is gaining recognition!! I was diagnosed 15 years ago and luckily had it removed with no lymph compromise! But at the time I was dismissed as having "not real cancer" by family and friends! Love my massive hole in my leg! and anyone that asks about it I advise them to stay out of the sun and cover up! xx
🌻 for you my friend. 😊🍀
Thank you understand a little more now
MPA advocates for equitable access to the best evidence-based treatment options for all Australian melanoma patients.
The Pharmaceutical Benefits Advisory Committee (PBAC) will consider the following important melanoma drugs for listing on the Pharmaceutical Benefits Scheme (PBS) at their March 2019 meeting.
1. Nivolumab (Opdivo) for “adjuvant” treatment of patients who have had completely surgically resected Stage III or Stage IV melanoma.
This is the second time this drug is being considered by the PBAC for treatment in the adjuvant setting as it was not accepted at the July 2018 meeting.
2. Dabrafenib (Tafinlar) and Trametinib (Mekinist) for “adjuvant” treatment of resected Stage III melanoma in BRAF mutation positive patients.
Clinical trials have shown these drugs significantly reduce the likelihood of recurrence.
MPA will make a submission on behalf of our members.
The PBAC also very much welcomes submissions from patients and others. We encourage all melanoma patients and those affected, to take this opportunity to provide their personal accounts and experiences detailing why these drugs should be considered for PBS listing.
Closing date is Wed 13 February 2019.
You can submit an online comment to the PBAC for both submissions via the link below:
*** For Nivolumab (Opdivo) please choose the FIRST option in the drop-down box.
Best Regards - Victoria Beedle CEO
www.health.gov.au/internet/main/publishing.nsf/Content/PBAC_online_submission_form.
Helen Curtis
Done. Love to Alicia. Xo
Done ✅. Gave a pretty good submission just a couple of days prior to my 5 adjuvant nivo infusion. (Stage 4 .. surgical removal of lung tumour and axillary lymph .. tanks to the compassion of the drug company ... told em to do a deal .. spend a percentage on research in Australia !
I wish this was a option for my sister 3 months ago:(
Very difficult to understand how it works and not only for myself but for my oncologist. Can you shed some light, I am stage 4 melanoma, have had two metastatic melanomas removed surgically. Currently I am on Opdivo as adjuvant treatment. I thought this had been approved on PBS for 1 December? It appears that it wasn’t with this application.
